DexCom is trading 4.37% higher at $87.12 following the company's announcement on October 14, 2026, that the CONNECT randomized trial results have been published in The New England Journal of Medicine. - The landmark trial showed Dexcom G7 users with Type 2 diabetes not using insulin achieved an average 1.6% A1C reduction, supporting broader continuous glucose monitoring (CGM) use. - This publication marks the first time in nearly two decades that NEJM has published clinical data on standalone real-time CGM technology.